CA2927735C - Combination therapies with psma ligand conjugates - Google Patents

Combination therapies with psma ligand conjugates Download PDF

Info

Publication number
CA2927735C
CA2927735C CA2927735A CA2927735A CA2927735C CA 2927735 C CA2927735 C CA 2927735C CA 2927735 A CA2927735 A CA 2927735A CA 2927735 A CA2927735 A CA 2927735A CA 2927735 C CA2927735 C CA 2927735C
Authority
CA
Canada
Prior art keywords
psma
antiandrogen
ligand
kit
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2927735A
Other languages
English (en)
French (fr)
Other versions
CA2927735A1 (en
Inventor
William C. Olson
Vincent Dipippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PSMA Development Co LLC
Original Assignee
PSMA Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PSMA Development Co LLC filed Critical PSMA Development Co LLC
Priority to CA3181096A priority Critical patent/CA3181096A1/en
Priority claimed from PCT/US2014/000124 external-priority patent/WO2015057250A1/en
Publication of CA2927735A1 publication Critical patent/CA2927735A1/en
Application granted granted Critical
Publication of CA2927735C publication Critical patent/CA2927735C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2927735A 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates Active CA2927735C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3181096A CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361893145P 2013-10-18 2013-10-18
US61/893,145 2013-10-18
US201361903589P 2013-11-13 2013-11-13
JP2013235506A JP6908964B2 (ja) 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法
US61/903,589 2013-11-13
JP2013-235506 2013-11-13
PCT/US2014/000124 WO2015057250A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3181096A Division CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Publications (2)

Publication Number Publication Date
CA2927735A1 CA2927735A1 (en) 2015-04-23
CA2927735C true CA2927735C (en) 2023-02-07

Family

ID=53009949

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2927735A Active CA2927735C (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
CA3181096A Pending CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3181096A Pending CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Country Status (4)

Country Link
EP (2) EP3827844A1 (https=)
JP (3) JP6908964B2 (https=)
AU (3) AU2014337391B2 (https=)
CA (2) CA2927735C (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020077259A1 (en) * 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
CN119792549A (zh) * 2021-04-23 2025-04-11 天津全和诚生物技术有限公司 缀合物及其制备方法和用途
WO2025125469A1 (en) * 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
WO2025216238A1 (ja) * 2024-04-09 2025-10-16 国立大学法人広島大学 薬物コンジュゲート又はその塩

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
EP2326350B1 (en) * 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
AU2010260195B2 (en) 2009-06-15 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability

Also Published As

Publication number Publication date
JP2023135666A (ja) 2023-09-28
AU2014337391B2 (en) 2020-06-11
JP2019194209A (ja) 2019-11-07
CA3181096A1 (en) 2015-04-23
EP3057614B1 (en) 2020-09-30
AU2014337391A1 (en) 2016-05-05
EP3827844A1 (en) 2021-06-02
JP2015078168A (ja) 2015-04-23
JP7716836B2 (ja) 2025-08-01
AU2020203191B2 (en) 2023-03-09
CA2927735A1 (en) 2015-04-23
JP6908964B2 (ja) 2021-07-28
AU2023200926A1 (en) 2023-03-23
EP3057614A1 (en) 2016-08-24
AU2020203191A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
AU2020203191B2 (en) Combination therapies with psma ligand conjugates
US20150110814A1 (en) Combination therapies with psma ligand conjugates
US20210023094A1 (en) Psma antibody-drug conjugates
US9242012B2 (en) Methods for killing PSMA-expressing, taxane-resistant cancer cells
JP2015523380A (ja) 抗ｃｄ７９ｂ抗体を含む免疫複合体
JP2019506136A (ja) 新規抗ｅｍｒ２抗体及び使用方法
CA3151322A1 (en) Combination therapy with immune stimulatory conjugates
JP2015529656A (ja) 抗ｅｔｂｒ抗体および免疫複合体
ES2837927T3 (es) Terapias de combinación con conjugados de ligando de PSMA
HK1116697B (en) Psma antibody-drug conjugates
HK1159474B (en) Compounds for killing psma-expressing, taxane- resistant cancer cells
HK1186110A (en) Psma antibody-drug conjugates

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190401

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509